In collaboration with Joanneum Research, the focus is on integrating multifunctional nanofibers into lab-on-chip (LoC) systems. These nanofibers serve various roles, including membranes, optical sensors, and drug delivery systems, revolutionizing how drugs are stored and uniformly released on LoC chips. Additionally, the use of nanofibers as elements for mixing, pumping, filtering, and sensing is being explored to enhance the precision and functionality of LoC systems.

A key aspect of the project involves embedding the nanofiber fabrication process, specifically electrospinning, into the mass production of LoC chips, highlighting the importance of economic scalability for these innovations.

The study also prioritizes the use of biogenic or biodegradable materials, accompanied by a thorough life cycle analysis across the entire value chain, ensuring that these advancements contribute to a more sustainable future

‍

Project coordinator:JOANNEUM RESEARCH Forschungsgesellschaft mbH

Project partner: NORGANOID GmbH,Genspeed Biotech GmbH,ViennaLab Diagnostics GmbH

FFG Funding, 2023 – 2026

GM1 gangliosidosis is a rare genetic disorder affecting 1 in every 100,000 to 200,000 births. It results from mutations in the GLB1 gene, leading to a deficiency in the beta-galactosidase enzyme, which causes severe neurological impairments and, tragically, early mortality. Current therapeutic options can only slow the disease’s progression rather than provide a cure.

In partnership with Tcelltech and the European GM1 Foundation, NORGANOID is leading pioneering research into gene therapy as a potential long-term solution for GM1 gangliosidosis. The goal is to address the disease at its genetic root, aiming not just to halt but to reverse its harmful effects. This approach is especially promising when applied early in the disease’s progression. By using patient-derived organoids to replicate the disease environment, we gain critical insights into the impact of beta-galactosidase enzyme deficiency. This research represents a significant shift from symptom management to directly targeting the underlying cause of the disease, leveraging advanced gene therapy techniques and the latest innovations in medical technology.

Project partner: Tcelltech GmbH, European GM1 Foundation

In partnership with the Austrian Center of Industrial Biotechnology (acib) and the Medical University of Graz, we address the complex fertility challenges that affect over 10% of couples worldwide, including those with endometriosis. This collaboration marks a significant advancement in understanding and overcoming fertility barriers.

The strategy involves creating patient-derived and patient-iPSCs-derived endometrial organoids that closely replicate the natural uterine environment. By comparing organoids from both fertility-challenged patients and healthy controls, deep insights into the cellular and molecular factors crucial for successful pregnancy are being explored. NORGANOID’s advanced OoC further enhances this research by precisely simulating the endometrial environment, offering unparalleled insights into the conditions necessary for implantation and gestation.

The application of omics technologies plays a central role in this research, enabling the examination of genetic, proteomic, and metabolic factors in fertility. This cutting-edge work aims to uncover novel biomarkers and therapeutic targets, potentially leading to more effective treatments and advancing personalized medicine in reproductive health.